Back to Search Start Over

Transcatheter Aortic Valve Replacement With a Repositionable Self-Expanding Prosthesis: The PORTICO-I Trial 1-Year Outcomes.

Authors :
Søndergaard L
Rodés-Cabau J
Hans-Peter Linke A
Fichtlscherer S
Schäfer U
Kuck KH
Kempfert J
Arzamendi D
Bedogni F
Asch FM
Worthley S
Maisano F
Source :
Journal of the American College of Cardiology [J Am Coll Cardiol] 2018 Dec 11; Vol. 72 (23 Pt A), pp. 2859-2867. Date of Electronic Publication: 2018 Sep 24.
Publication Year :
2018

Abstract

Background: The new self-expanding, repositionable transcatheter heart valve (THV) system was designed for treatment of severe, symptomatic aortic stenosis in patients with high surgical risk.<br />Objectives: The purpose of this study was to report 1-year outcomes of transcatheter aortic valve replacement with the new THV system.<br />Methods: This ongoing, international, multicenter study evaluated patients with severe, symptomatic aortic stenosis implanted with the THV via transfemoral access and follow-up at 30 days, 1 year, and annually through 5 years. The primary endpoint is all-cause mortality at 1 year; secondary endpoints include clinical outcomes and echocardiographic measurements, both adjudicated.<br />Results: A total of 941 patients (82.4 ± 5.9 years; 65.7% female; Society of Thoracic Surgeons Predicted Risk of Operative Mortality score: 5.8%) were enrolled and underwent an implant at 61 sites in Europe, Australia, and Canada. At 1 year, Kaplan-Meier estimates for all-cause mortality, cardiovascular mortality, disabling stroke rates, and myocardial infarction were 12.1%, 6.6%, 2.2%, and 2.5%, respectively. Mean aortic transvalvular gradient and aortic valve area were 8.66 mm Hg and 1.75 cm <superscript>2</superscript> , respectively. Paravalvular leakage was moderate or higher in 2.6% of patients with no severe leakage. New pacemaker rates were 18.7% and 21.3% for pacemaker naïve patients at 30 days and 1 year, respectively. Functional class, exercise capacity, and quality of life improved significantly from baseline to 1 year.<br />Conclusions: Transcatheter aortic valve replacement with the new THV in patients who are at increased surgical risk is associated with low 1-year mortality and stroke rates. Favorable hemodynamic results at 1 year are observed with low transvalvular pressure gradient and incidence of significant paravalvular leakage. (5 Year Observation of Patients With PORTICO Valves [PORTICO-I]; NCT01802788).<br /> (Copyright © 2018 American College of Cardiology Foundation. All rights reserved.)

Details

Language :
English
ISSN :
1558-3597
Volume :
72
Issue :
23 Pt A
Database :
MEDLINE
Journal :
Journal of the American College of Cardiology
Publication Type :
Academic Journal
Accession number :
30261238
Full Text :
https://doi.org/10.1016/j.jacc.2018.09.014